Heart shield? diabetes drug tested to prevent chemo damage in breast cancer
NCT ID NCT06427226
First seen Apr 18, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tests if dapagliflozin, a drug used for diabetes, can prevent heart damage caused by the chemotherapy drug doxorubicin in breast cancer patients. About 46 adults with early-stage breast cancer who have not had chemo before will take dapagliflozin or a placebo during their treatment. The main goal is to see if the drug helps keep the heart pumping normally.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical Research Institute
RECRUITINGAlexandria, Bab Sharqi, 21526, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.